OncoResponse: Developer of therapeutic antibodies designed to provide care against immuno-oncology targets. The company's technology leverages the human immune system to identify fully human monoclonal antibodies and discover novel targets that will lead to the development of antibody-derived therapeutics for the treatment of cancer, providing a larger number of cancer patients with the benefit of immunotherapy.
Based in...
US - Pacific
Clinical Stage
Pre-Clinical Stage
Disease Space
Immuno-Oncology, Immunotherapy, Oncology
Investment Participation
CrossOvers, Series C
Therapeutic Modalities
Antibodies, Platform Technology
1124 Columbia Street
Suite 300
Seattle, WA 98104
United States

Company Participants at Fall Private Company Showcase 2020

Clifford J. Stocks
OncoResponse, CEO/Co-Founder
Mr. Stocks brings more than twenty-eight years of experience in the biotech industry to OncoResponse. Most recently, Mr. Stocks served as Chief Executive Officer at Theraclone Sciences, where he was responsible for leading all aspects of the company’s efforts to discover and develop novel therapeutic antibody immunotherapies for the treatment of infectious disease. Prior to Theraclone, Mr. Stocks served as Chief Business Officer of Calistoga Pharmaceuticals, Inc., where he led the partnering activities and M&A teamwork that resulted in the acquisition of Calistoga by Gilead for $600 million in Q2 2011. Prior to Calistoga, Mr. Stocks spent over 15 years at ICOS Corporation, where he served as an Executive Officer and Vice President of Business Development. While at ICOS, he led acquisitions and joint venture activities, as well as alliance formation, strategy, licensing and deal making. He played an instrumental role on the leadership team that developed and launched Cialis®, and was a key architect of the Lilly ICOS joint venture partnership leading to the $2.3 billion acquisition of ICOS in 2007. Mr. Stocks's early career includes a turn as a management consultant in the Health Services practice of Booz, Allen & Hamilton, as well as academic research in the department of immunology at the University of Utah and the department of molecular genetics and cell biology at the University of Chicago. Mr. Stocks received a Master of Business Administration degree from the University of Chicago, Booth Graduate School of Business and a Bachelor of Science degree in biology from the University of Utah.